According to filings with the U.S. Securities and Exchange Commission, Atsena Therapeutics is raising $32,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Patrick Ritschel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. We have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Our additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease. Founded by ocular gene therapy pioneers Dr. Shannon Boye and Sanford Boye, Atsena has strong ties with the University of Florida. Our offices are located in Durham, NC, an environment rich in gene therapy expertise, and northern NJ.

To learn more about Atsena Therapeutics, visit http://atsenatx.com/

Contact:
Patrick Ritschel, Chief Executive Officer
984-261-2001
https://www.linkedin.com/in/patrick-ritschel-aa949160/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.